PHARMACOSMOS CONTINUES STRONG GROWTH TRAJECTORY

Holbaek, 1 July 2026

Highlights for the Period 1 May 2025 to 30 April 2026

• Revenue for the period increased by 14% to DKK 3,827 million (2024/25: DKK 3,362 million).

• During 2025/26, Pharmacosmos established a Canadian affiliate to strengthen its market presence in Canada.

• Continued commercial momentum across key markets, especially the USA and Europe.

• Operating profit for the year totalled DKK 987 million (2024/25: DKK 833 million).

• Net profit was DKK 756 million (2024/25: DKK 1,652 million).

• For 2026/27 revenue is expected in the range of DKK 4.0 to 4.2 billion, reflecting continued strong underlying growth in Pharmaceuticals, partly offset by the transition to a partnership model in China. The group's operating profit is expected to be around DKK 1.0 billion.

Key Financial Figures

(DKK million.)

2025/26

• Revenue: 3,827

• Operating profit: 987

• Net profit: 756

• Net cash flows from operating activities: 1,636

• Equity: 3,044

• Average no. of FTEs: 719

2024/25

• Revenue: 3,362

• Operating profit: 833

• Net profit: 1,652(*)

• Net cash flows from operating activities: 2,142 (*)

• Equity: 2,273

• Average no. of FTEs: 652

(*) 2024/25 net profit and cash flow figures were positively impacted by other operating income of DKK 1,494 million, primarily relating to legal settlements.

(Source: Pharmacosmos Holding A/S, Annual Report 2025/26)

Tobias S. Christensen, President & CEO, said in connection with the publication of the financial statements:

“2025/26 was another strong year for Pharmacosmos. We delivered growth across our subsidiaries, increased our profitability, and continued to strengthen the company for the future. During the year, we expanded our global presence through the establishment of a Canadian affiliate and continued to invest in our commercial business, clinical development programmes, and organisational capabilities”

About Pharmacosmos

Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anaemia. Building on our foundational expertise in carbohydrate chemistry and cell cycle biology, we develop innovative treatments for unmet patient needs, with a focus on iron metabolism and blood-related disorders. Founded in 1965 and headquartered in Denmark, our team is made up of more than 650 specialists across the UK, Ireland, the Nordics, Germany, Canada, and the USA.

Contact

Christian Lundquist Madsen,
Vice President Global Marketing & Communication
+45 5948 5959
clm@pharmacosmos.com